Naveen Pemmaraju, MD, discusses the current understandings of how myelofibrosis presents in patients.
Naveen Pemmaraju, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the current understandings of how myelofibrosis (MF) presents in patients.
MF is a heterogenous disease and can present in a number of different ways, says Pemmaraju. For patients with low-risk disease, according to the International Prognostic Scoring System, MF will present similarly to a chronic disease, such as essential thrombocytopenia or polycythemia vera. Life expectancy can be measured in decades for these patients. However, patients who present with intermediate- to high-risk disease may be ill when they come into the clinic; they present with various symptoms and can become sick quickly from the disease itself.
Participants Discuss Treating a Patient With Myelofibrosis and Anemia
March 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More